Abstract
1α, 25-dihydroxyvitamin D3 [1,25 (OH)2D3], the active metabolite of vitamin D3, is known for the maintenance of normal skeleton architecture and mineral homeostasis. Apart form these traditional calcemic actions, 1,25 (OH)2D3 and its synthetic analogs are increasingly recognized for their potent anti-proliferative, prodifferentiative and immunomodulatory activities. The calcemic and non-calcemic actions of 1,25 (OH)2D3 and its synthetic analogs are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid / thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25 (OH)2D3 in various systems, along with the detection of VDR in target cells, have indicated potential applications of VDR ligands in inflammation, dermatological indications, osteoporosis, cancers and autoimmune diseases. VDR ligands have shown therapeutic potential in limited clinical trials as well as in animal models of these diseases. As a result, a VDR ligand, calcipotriol is in clinic for psoriasis and another, OCT, [2-oxa-1,25 (OH)2D3] is being developed as a topical agent for the same indication. Further, 1α,-hydroxyvitamin D3 (alphacalcidol), a prodrug of 1,25 (OH)2D3 is in clinic and a synthetic VDR ligand, ED-71, is under consideration for approval in Japan for the treatment of osteoporosis. Interestingly, VDR ligands have shown not only preventive but also potent therapeutic anabolic activities in animal models of osteoporosis. However, the wide spread use of VDR ligands in above-mentioned indications is hampered by their major side effect, namely hypercalcemia. In view of this associated toxicity, synthetic VDR ligands with reduced calcemic potential have been synthesized with the ultimate aim of improving their therapeutic efficacy. This review presents recent advances in VDR biology, novel VDR ligands and therapeutic applications of VDR ligands.
Keywords: 25-dihydroxyvitamin, immunomodulatory, VDR ligands, osteoporosis, hydroxyvitamin
Mini-Reviews in Medicinal Chemistry
Title: Vitamin D Receptor as a Drug Discovery Target
Volume: 3 Issue: 3
Author(s): Karen V. Pinette, Ying K. Yee, Bernard Y. Amegadzie and Sunil Nagpal
Affiliation:
Keywords: 25-dihydroxyvitamin, immunomodulatory, VDR ligands, osteoporosis, hydroxyvitamin
Abstract: 1α, 25-dihydroxyvitamin D3 [1,25 (OH)2D3], the active metabolite of vitamin D3, is known for the maintenance of normal skeleton architecture and mineral homeostasis. Apart form these traditional calcemic actions, 1,25 (OH)2D3 and its synthetic analogs are increasingly recognized for their potent anti-proliferative, prodifferentiative and immunomodulatory activities. The calcemic and non-calcemic actions of 1,25 (OH)2D3 and its synthetic analogs are mediated through vitamin D receptor (VDR), which belongs to the superfamily of steroid / thyroid hormone nuclear receptors. Physiological and pharmacological actions of 1,25 (OH)2D3 in various systems, along with the detection of VDR in target cells, have indicated potential applications of VDR ligands in inflammation, dermatological indications, osteoporosis, cancers and autoimmune diseases. VDR ligands have shown therapeutic potential in limited clinical trials as well as in animal models of these diseases. As a result, a VDR ligand, calcipotriol is in clinic for psoriasis and another, OCT, [2-oxa-1,25 (OH)2D3] is being developed as a topical agent for the same indication. Further, 1α,-hydroxyvitamin D3 (alphacalcidol), a prodrug of 1,25 (OH)2D3 is in clinic and a synthetic VDR ligand, ED-71, is under consideration for approval in Japan for the treatment of osteoporosis. Interestingly, VDR ligands have shown not only preventive but also potent therapeutic anabolic activities in animal models of osteoporosis. However, the wide spread use of VDR ligands in above-mentioned indications is hampered by their major side effect, namely hypercalcemia. In view of this associated toxicity, synthetic VDR ligands with reduced calcemic potential have been synthesized with the ultimate aim of improving their therapeutic efficacy. This review presents recent advances in VDR biology, novel VDR ligands and therapeutic applications of VDR ligands.
Export Options
About this article
Cite this article as:
Pinette V. Karen, Yee K. Ying, Amegadzie Y. Bernard and Nagpal Sunil, Vitamin D Receptor as a Drug Discovery Target, Mini-Reviews in Medicinal Chemistry 2003; 3 (3) . https://dx.doi.org/10.2174/1389557033488204
DOI https://dx.doi.org/10.2174/1389557033488204 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Update on Pathogenesis of Sjogren's Syndrome
Current Rheumatology Reviews Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Role of Leptin in the Immune System
Current Immunology Reviews (Discontinued) Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Biological Therapies of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Current Medicinal Chemistry Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design miRNA Functions in Arthritis
Current Rheumatology Reviews